Welcome to our dedicated page for NH news (Ticker: NH), a resource for investors and traders seeking the latest updates and insights on NH stock.
NantHealth (NH) delivers innovative healthcare solutions through its unique integration of advanced diagnostics and comprehensive data analytics. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in precision medicine.
Access timely reports on clinical developments, technology partnerships, and operational milestones that shape NH's position in healthcare innovation. Our curated collection includes earnings announcements, regulatory filings, product launch details, and strategic collaborations within the medical technology sector.
Key areas of coverage feature NH's systems-based approach to treatment optimization, advancements in biometric data integration, and initiatives supporting value-based care models. Stay informed about developments impacting personalized healthcare delivery and diagnostic technology evolution.
Bookmark this page for streamlined access to verified NH updates. Check regularly for new insights into how the company continues bridging healthcare services with actionable data solutions.
NantHealth announced a significant multi-year renewal agreement with a leading nonprofit health plan, enhancing its Eviti Connect for Oncology platform. This expansion introduces radiation therapy validation and care navigation services, impacting over two million members across six states. The new services aim to streamline cancer treatment processes, improve member experiences, and reduce administrative burdens on healthcare providers. The agreement underscores NantHealth's commitment to delivering evidence-based, patient-centric care.
NantHealth has achieved HITRUST certification for its NaviNet Open platform, solidifying its commitment to data security and regulatory compliance. This certification places NantHealth among an elite group globally recognized for their information security management. NaviNet Open enhances communication between providers, supporting over 500,000 users and facilitating more than 33 million transactions monthly. Senior VP Chris House emphasized that this certification demonstrates their leadership in healthcare IT and assures clients of high standards for data protection.
NantHealth reported Q4 2021 revenue of $16.0 million, a decline from $18.6 million in Q4 2020, with a gross margin of 57%. For the full year, revenue was $62.6 million, down from $73.2 million in 2020. The net loss for Q4 was $16.7 million ($0.14 per share), improving from $20.1 million ($0.18 per share) year-over-year. Noteworthy operational developments included the launch of Eviti Connect for Autoimmune Diseases and significant growth in the NaviNet AllPayer Advantage segment, which saw 17% year-over-year growth.
NantHealth, Inc. (NASDAQ: NH) will announce its 2021 fourth quarter and full year financial results on February 24, 2022, after market close. Following the announcement, the management will host a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss performance details. Interested parties can join by calling 877-407-0312 from the U.S. or 201-389-0899 internationally, or listen via www.nanthealth.com.
NantHealth, Inc. (NASDAQ: NH) has launched its first OpenNMS Minion Appliance, enhancing the deployment of its monitoring system. This cloud-enabled appliance simplifies the setup and extension of OpenNMS Minion in remote networks. It features a user-friendly portal for configuration and diagnostics, along with automated updates. CEO David Hustace emphasizes its significance for growing corporate networks. Built with Azure IoT and Ubuntu Core, the appliance supports both current on-premise and future cloud solutions.
NantHealth (NASDAQ: NH) has announced that Maryland Physicians Care (MPC) will utilize its Eviti Connect for Autoimmune Diseases solution. This initiative aims to enhance drug authorization processes for members with chronic autoimmune conditions. The platform will improve visibility into drug costs, support reimbursements, and reduce denials while optimizing patient care.
Dr. Jonathan Keyser, Director of Pharmacy at MPC, emphasized the commitment to provide high-quality healthcare through innovative programs. NantHealth's COO Ron Louks noted that the collaboration aligns with their mission to improve patient care efficiency.
NantHealth, Inc. (NASDAQ: NH) announced participation in the 2021 Jefferies London Healthcare Conference. The event will feature virtual meetings with institutional investors on November 18 and 19, 2021. NantHealth aims to showcase its enterprise solutions that enable businesses to transform complex data into actionable insights across various sectors, including healthcare and life sciences. For scheduling meetings, interested parties should contact their Jefferies representative.
NantHealth, Inc. (NH) reported Q3 2021 net revenue of $14.4 million, down from $18.8 million in Q3 2020, attributed to contract expirations and initiations. Gross margin decreased to 52% from 60% year-over-year. SG&A expenses rose to $13.0 million, while R&D expenses slightly decreased to $4.6 million. The net loss narrowed to $10.8 million ($0.09 per share). Cash reserves stand at $45.5 million. NantHealth aims for a return to average revenue run rates in Q4 and continues to expand its Eviti Connect program, enhancing product offerings.
NantHealth, Inc. (NASDAQ: NH) has appointed three new executives to enhance its leadership team: Jerry Magin as Senior VP of Global Sales and Marketing, Neil Carpenter as Senior VP of Strategy, and Arlyn Small as Senior VP of Human Resources. Magin brings over 25 years of experience in building sales and marketing teams, Carpenter has extensive expertise in healthcare strategy, while Small has a strong background in HR across multiple sectors. These appointments aim to drive growth and innovation at NantHealth, as stated by COO Ron Louks.
NantHealth, Inc. (NASDAQ-GS: NH) will announce its 2021 third quarter financial results on November 4, 2021, after market close. The company will hold a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss its performance. Interested parties can join the call by dialing 800-584-1507 for U.S. and Canada or 212-231-2902 for international access. The call will also be available online at nanthealth.com.
